oral NMDAR positive allosteric modulator

Ph. II candidate in neurology

from previously disclosed PAM and opt

J. Med. Chem.

Sage Therapeutics, Inc., Cambridge, MA

SAGE-718 Chemical Structure oral NMDAR positive allosteric modulator - Sage Therapeutics, Inc., Cambridge, MA

Context. SAGE-718 (Sage Therapeutics) is an oral N-methyl-d-aspartate receptor (NMDAR) Positive Allosteric Modulator (PAM) being developed for cognitive impairment in Huntington’s disease. Aberrant NMDAR signaling has been implicated in…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: